利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

215 条记录 (耗时 0.049 秒)

    Peptide compounds
    23.
    发明授权
    Peptide compounds 失效
    肽化合物

    公开(公告)号：US5882645A

    公开(公告)日：1999-03-16

    申请号：US374560

    申请日：1995-03-13

    申请人： Istvan Toth ,  William Anthony Gibbons

    发明人： Istvan Toth ,  William Anthony Gibbons

    IPC分类号： A61K39/00 ,  A61K47/48 ,  A61K51/08 ,  A61K51/12 ,  A61P37/04 ,  C07K14/00 ,  C07K14/09 ,  C07K14/295 ,  A61K39/385 ,  A61K38/00

    CPC分类号： C07K14/005 ,  A61K47/48238 ,  A61K47/4833 ,  A61K47/48815 ,  A61K51/088 ,  C07K14/001 ,  C07K14/295 ,  A61K39/00 ,  C07K2319/40 ,  C12N2770/32122

    摘要： Synthetic peptides are widely used to generate antibodies. To induce high antibody response, it is known to conjugate the peptide to a carrier protein (e.g. KLH, BSA) or to incorporate it into polylysine to form a multiple antigenic peptide. Anchors may be built in which are based on fatty acids. According to the invention there is provided a novel lipidic amino acid based anchor system which can maximally enhance the antigenicity of a short synthetic peptide. These novel compounds are entirely peptide-based and may therefore be produced automatically by some step wise peptide synthesis, preferably solid phase step wise peptide synthesis. According to the invention there is also provided such a process.

    摘要翻译： PCT No.PCT / GB93 / 01558 Sec。 371日期1995年3月13日 102（e）1995年3月13日PCT PCT 1993年7月23日PCT公布。 公开号WO94 / 02506 日期1994年2月3日合成肽广泛用于产生抗体。 为了诱导高抗体应答，已知将肽与载体蛋白（例如KLH，BSA）缀合或将其掺入聚赖氨酸以形成多重抗原肽。 可以建立基于脂肪酸的锚点。 根据本发明，提供了一种新的基于脂质氨基酸的锚定系统，其可以最大程度地增强短合成肽的抗原性。 这些新化合物完全是基于肽的，因此可以通过一些逐步的肽合成自动产生，优选为固相步骤肽合成。 根据本发明，还提供了这种方法。

    Method of causing selective immunosuppression using HL-60-related lectins
    25.
    发明授权
    Method of causing selective immunosuppression using HL-60-related lectins 失效
    使用HL-60相关凝集素引起选择性免疫抑制的方法

    公开(公告)号：US5710257A

    公开(公告)日：1998-01-20

    申请号：US719551

    申请日：1996-09-25

    申请人： Jeffrey J. Seilhamer ,  Glenn Nedwin ,  Tim Bringman ,  Pierre-Olivier Couraud

    发明人： Jeffrey J. Seilhamer ,  Glenn Nedwin ,  Tim Bringman ,  Pierre-Olivier Couraud

    IPC分类号： A61K38/00 ,  A61K38/16 ,  A61K38/17 ,  A61K39/395 ,  A61K47/48 ,  A61P37/06 ,  C07K14/47 ,  C12N15/00 ,  C07K14/00

    CPC分类号： A61K38/1709 ,  A61K38/168 ,  A61K39/395 ,  A61K47/48261 ,  A61K47/4833 ,  C07K14/4726 ,  Y10S530/827

    摘要： Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.

    摘要翻译： 可用于治疗自身免疫病症的药物组合物包括作为活性成分的分子量为约14千道尔顿的可溶性凝集素或其片段。 凝集素或片段与β-半乳糖苷含量部分无关，与Ca 2+的存在或不存在无关，刺激胰蛋白酶化的兔红细胞血凝反应，其中刺激被乳糖或硫代半乳糖苷抑制，其氨基酸序列至少含有 一个N-糖基化位点，并且与图1的位置2-135所示的氨基酸序列至少90％同源。 1或其相关部分。 该组合物用于治疗自身免疫病症如类风湿性关节炎，重症肌无力和多发性硬化，以及调节过敏反应或器官或组织移植排斥反应中的免疫应答。 本发明组合物可与一般免疫抑制剂组合。

    Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
    26.
    发明授权
    Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines 失效
    百日咳毒素在缀合疫苗中用作非带电糖的载体蛋白

    公开(公告)号：US5445817A

    公开(公告)日：1995-08-29

    申请号：US932960

    申请日：1992-08-21

    申请人： Rachel Schneerson ,  Lily Levi ,  John B. Robbins

    发明人： Rachel Schneerson ,  Lily Levi ,  John B. Robbins

    IPC分类号： A61K39/116 ,  A61K47/48 ,  A61K39/385 ,  A61K39/09 ,  A61K39/10

    CPC分类号： A61K47/4833 ,  A61K39/092 ,  A61K2039/6037 ,  Y10S424/831

    摘要： A medically important and useful conjugate comprising pertussis toxin (PT), or another antigen having similar physico-chemical properties, as the carrier protein component, coupled to a neutral or non-charged saccharide, particularly, the capsular polysaccharide of Streptococcus pneumoniae type 14 (Pn14), for use as an effective, non-toxic, and highly immunogenic vaccine is described. The invention is directed to a novel synthetic scheme wherein PT and like proteins, and a derivative of Pn14, and the like, were coupled at acidic pH via carbodiimide-mediated condensation to produce an immunogenic conjugate. The coupling procedure yielded a Pn14-PT conjugate in which the PT component was rendered non-toxic and both the PT and Pn14 components were immunogenic, as determined by the production of protective levels of both type-specific and neutralizing antibodies in mammals. The Pn14-PT conjugate was used as an immunogen at levels estimated to be protective in humans and stands to provide an effective, safe, and potent human vaccine.

    摘要翻译： 包含百日咳毒素（PT）或具有相似物理化学性质的另一抗原作为载体蛋白组分的医学上重要且有用的缀合物偶联到中性或非带电糖，特别是14型肺炎链球菌的荚膜多糖（ Pn14）用作有效，无毒，高免疫原性疫苗。 本发明涉及一种新颖的合成方案，其中PT等蛋白质和Pn14衍生物等通过碳二亚胺介导的缩合在酸性pH下偶联以产生免疫原性缀合物。 偶联方法产生Pn14-PT缀合物，其中PT组分无毒，并且PT和Pn14组分都是免疫原性的，如通过哺乳动物中特异性和中和抗体的保护水平的产生所确定的。 Pn14-PT缀合物用作免疫原，其水平估计在人体中是保护性的，并且提供有效，安全和有效的人类疫苗。

    Method for immunization against and treatment of infection by ectoparasites and endoparasites
    28.
    发明授权
    Method for immunization against and treatment of infection by ectoparasites and endoparasites 失效
    免疫接种和治疗外寄生虫和内寄生虫感染的方法

    公开(公告)号：US4814170A

    公开(公告)日：1989-03-21

    申请号：US839892

    申请日：1986-03-14

    申请人： Stephen L. Karr, Jr.

    发明人： Stephen L. Karr, Jr.

    IPC分类号： A61K39/00 ,  A61K39/395 ,  A61K39/44 ,  A61K47/48 ,  A61P33/02 ,  A61K37/24

    CPC分类号： A61K47/4833 ,  A61K39/0003 ,  A61K39/44 ,  A61K2039/6081

    摘要： This invention relates to a method for the active or passive immunization of a vertebrate against ectoparasites and endoparasites, and a method of treating a vertebrate host infected by ectoparasites or endoparasites, comprising administering to the vertebrate an immunogen comprising one or more endocrine products of ectoparasites and endoparasites, coupled with an immunogenic carrier, or administering to the vertebrate, monoclonal antibodies formed to said immunogen.

    摘要翻译： 本发明涉及一种针对外寄生虫和内寄生虫的脊椎动物的主动或被动免疫的方法，以及一种治疗由外寄生虫或内寄生虫感染的脊椎动物宿主的方法，包括向脊椎动物施用包含一种或多种外寄生物的内分泌产物的免疫原和 再加上免疫原性载体，或向脊椎动物施用形成于所述免疫原的单克隆抗体。

    Bupropion radioimmunoassay, and kit
    29.
    发明授权
    Bupropion radioimmunoassay, and kit 失效
    安非他酮放射免疫测定和试剂盒

    公开(公告)号：US4356165A

    公开(公告)日：1982-10-26

    申请号：US140158

    申请日：1980-04-14

    申请人： John W. A. Findlay ,  Robert F. Butz ,  Richard M. Welch

    发明人： John W. A. Findlay ,  Robert F. Butz ,  Richard M. Welch

    IPC分类号： A61K47/48 ,  A61K51/04 ,  C07C45/00 ,  C07C45/54 ,  C07C45/56 ,  C07D263/04 ,  C07D263/10 ,  G01N33/56 ,  B65D71/00 ,  G01N33/60

    CPC分类号： C07D263/10 ,  A61K47/4833 ,  A61K51/0406 ,  C07C255/00 ,  C07C45/00 ,  C07C45/54 ,  C07C45/56 ,  C07D263/04

    摘要： A radioimmunoassay proceedure has been discovered for bupropion [(.+-.)-2-t-butylamino-3-chloropropiophenone], an antidepressant compound, in biological fluids. Novel compounds of formula ##STR1## wherein either R.sub.2 is oxygen and R.sub.1 is (CH.sub.2).sub.n --O--(CO).sub.m --(CH.sub.2).sub.p --COOH where n is an integer from 0 to 5, m is 0 or 1, and p is an integer from 1 to 4; or R.sub.1 is hydrogen and R.sub.2 is N--O--(CH.sub.2).sub.q --COOH where Q is an integer from 1 to 3, and novel methods of making them and novel intermediates useful therein are disclosed. Novel immunogens for raising bupropion specific antisera, and novel methods of making them are disclosed comprising conjugates of the novel compounds and suitable carrier material. The drug is added to the antisera together with novel radiolabeled competitor of formula ##STR2## wherein R' is a suitable radioisotope as described above and R.sub.3 is hydrogen, R.sub.4 is Cl, and R.sub.5 is oxygen, orR' is hydrogen and either(a) R.sub.3 is H and R.sub.4 is Cl and R.sub.5 is NO(CH.sub.2).sub.q CO-X where q is as defined for formula I and X is a group having formula III ##STR3## wherein R.sub.6 is a suitable radioisotope as described above, R.sub.7 is hydroxyl, and s is an integer from 1 to 4;(b) R.sub.4 is Cl, R.sub.5 is oxygen, and R.sub.3 is (CH.sub.2).sub.n --O--(CO).sub.m --(CH.sub.2).sub.p --CO--X where n, m, and p are as defined for formula I and X is as defined above; or(c) R.sub.3 is hydroxy, R.sub.5 is oxygen and R.sub.4 is a suitable radioisotope as defined above. The measure of radioactivity of the antisera bound radiolabeled competitor provides a measure of the amount of drug in the assayed biological fluid sample. A standard curve can be constructed from which the amount of drug in the assay sample can be interpolated. A kit is disclosed for practicing the radioimmunoassay.

    摘要翻译： 已经发现了用于生物液体中的安非他酮[（+/-） - 2-叔丁基氨基-3-氯苯丙酮]的放射免疫测定法，一种抗抑郁药。 式（IMA）的新型化合物，其中R2是氧，R1是（CH2）nO-（CO）m-（CH2）p-COOH，其中n是0-5的整数，m是0或1，p是 1到4的整数; 或R 1为氢，R 2为N-O-（CH 2）q -COOH，其中Q为1至3的整数，并且公开了制备它们的新方法和可用于其中的新型中间体。 公开了用于提高安非他酮特异性抗血清的新型免疫原及其制备方法，其包括新化合物和合适的载体材料的缀合物。 将药物与新的放射性标记的式（IMAGE）竞争剂一起加入到抗血清中，其中R'是如上所述的合适的放射性同位素，R 3是氢，R 4是Cl，R 5是氧，或者R'是氢， ）R3是H，R4是Cl，R5是NO（CH2）qCO-X，其中q如式I所定义，X是具有式III的基团，其中R6是如上所述的合适的放射性同位素，R7是 羟基，s为1至4的整数; （b）R4是Cl，R5是氧，R3是（CH2）nO-（CO）m-（CH2）p-CO-X，其中n，m和p如式I所定义，X如上定义 以上; 或（c）R3是羟基，R5是氧，R4是如上定义的合适的放射性同位素。 抗血清结合的放射性标记的竞争者的放射性测量值提供测定的生物流体样品中药物的量的量度。 可以构建标准曲线，由此可以插入测定样品中的药物量。 公开了用于实施放射免疫测定的试剂盒。